Why the study?
Does a biodegradable poly-l-lactic acid coronary stent show sufficient biocompatibility and strength compared to Palmaz-Schatz stents in porcine coronary arteries?
Does a biodegradable poly-l-lactic acid coronary stent show sufficient biocompatibility and strength compared to Palmaz-Schatz stents in porcine coronary arteries?
The biodegradable PLLA coronary stent demonstrated sufficient biocompatibility and strength comparable to bare metal stents in a porcine model, supporting further clinical trials.
Answers are grounded in this paper and cite their sources.
Comparable porcine outcomes support PLLA stent development; leaves open human safety and efficacy.
Although biocompatibility of biodegradable stents is controversial, stents made of high molecular weight poly‐ l ‐lactic acid (PLLA) are thought to be the most promising. We investigated the biocompatibility of PLLA stents histologically and angiographically in porcine coronary arteries. The Igaki‐Tamai stent is made of PLLA monofilaments (molecular mass 183 kD) with a zigzag helical coil design. Fourteen PLLA stents in 6 pigs and 9 Palmaz‐Schatz half stents in 9 pigs were implanted in 15 normocholesterolemic pigs. Stents were mounted on a delivery catheter, and were implanted percutaneously into coronary arteries. Coronary angiography was performed before and immediately after stenting, at 2 and 6 weeks in five PLLA pigs and nine Palmaz‐Schatz pigs. Histological studies were performed in PLLA pigs: 2 pigs at 2 weeks, 3 pigs at 6 weeks, and 1 pig at 16 weeks with hematoxylin‐eosin and elastica van Giesons stains. All PLLA stents were successfully delivered. No stent thrombosis was detected in either group. There were no significant differences in minimal lumen diameter (MLD) or percent diameter stenosis between the PLLA and Palmaz‐Schatz stent groups immediately after implantation, or at 2 or 6 weeks after implantation. Histological studies at 2, 6, and 16 weeks revealed no inflammation and minimal neointimal coverage on the PLLA stent struts. The PLLA stent maintained its structure for up to 16 weeks. These results suggest sufficient biocompatibility and strength of PLLA biodegradable stents in porcine coronary arteries. Clinical trial is now underway to validate the safety and usefulness of PLLA stents in humans.
No takes yet. Share an insight, caveat, or question.
Tamai et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: